Concepedia

Efficacy Boundaries

Efficacy Boundaries is a statistical decision rule in sequential testing that defines the threshold criteria for rejecting the null hypothesis at interim analyses, distinguishing it from futility or safety boundaries by focusing specifically on detecting a predefined clinically meaningful treatment effect.

6

Publications

927

Citations

52

Authors

39

Institutions

Publications per year

2017–2026

4

Variants

Efficacy Stopping Boundaries

Parents

Publications

6

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Charles M. Rudin, Mark M. Awad, Alejandro Navarro et al. · Journal of Clinical Oncology · 2020 · 759 citations · Full text

, , +14

Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

Yin Liu, Xiu-Zhi Zhu, Yi Xiao et al. · Cell Research · 2023 · 65 citations · Full text

, , +16

Design and Monitoring of Multi-Arm Multi-Stage Clinical Trials

Pranab Ghosh, Lingyun Liu, Pralay Senchaudhuri et al. · Biometrics · 2017 · 53 citations · Full text

, , +14

Interim evaluation of efficacy or futility in group‐sequential trials with multiple co‐primary endpoints

Koko Asakura, Toshimitsu Hamasaki, Scott Evans · Biometrical Journal · 2016 · 19 citations · Full text

, , +16

Nurse- vs Nomogram-Directed Glucose Control in a Cardiovascular Intensive Care Unit

C. A. Chant, M. Mustard, Kevin E. Thorpe et al. · American Journal of Critical Care · 2012 · 17 citations

, , +16

1–5 of 6

Authors

52

  1. PG
    Pranab Ghosh

    Pfizer (United States), United States

    2 publications · 67 citations

    2

    h-index

  2. CR
    Cyrus R. Mehta

    Cytel (United States), United States

    2 publications · 67 citations

    2

    h-index

  3. VE
    Victoria Ebiana

    Merck & Co., Inc., Rahway, NJ, USA (United States), United States

    1 publications · 759 citations

    1

    h-index

  4. AC
    A‐Yong Cao

    Fudan University Shanghai Cancer Center, China

    1 publications · 65 citations

    1

    h-index

  5. FO
    Francesco Orlandi

    Instituto Nacional del Tórax, Chile

    1 publications · 759 citations

    1

    h-index

1–5 of 52

Institutions

39

  1. Cytel (United States)

    Cambridge, United States

    2 h-index

    6 publications

    240 citations

  2. Harvard University

    Cambridge, United States

    2 h-index

    2 publications

    67 citations

  3. University of Toronto

    Toronto, Canada

    1 h-index

    1 publications

    759 citations

  4. Peking University Cancer Hospital

    Beijing, China

    1 h-index

    1 publications

    65 citations

  5. The University of Osaka

    Osaka, Japan

    1 h-index

    2 publications

    38 citations

  6. Dana-Farber Cancer Institute

    Boston, United States

    1 h-index

    1 publications

    759 citations

  7. University of Michigan

    Ann Arbor, United States

    1 h-index

    1 publications

    759 citations

  8. Centre Hospitalier Universitaire de Toulouse

    Toulouse, France

    1 h-index

    1 publications

    759 citations

1–8 of 39

Venues

  1. Cell Research

    1 publications · 65 citations

    1

    h-index

  2. Biometrics

    1 publications · 53 citations

    1

    h-index

  3. Biometrical Journal

    1 publications · 19 citations

    1

    h-index

  4. Statistics in Medicine

    1 publications · 14 citations

    1

    h-index

  5. Journal of Clinical Oncology

    1 publications · 759 citations

    1

    h-index

1–5